Comparative Pharmacology
Head-to-head clinical analysis: CHOLAC versus CO LAV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLAC versus CO LAV.
CHOLAC vs CO-LAV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic pH. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
15-30 mL (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 mL/day. For hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
None Documented
None Documented
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Unknown
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
CO-LAV is not a recognized drug. Please check the drug name.
Category C
Category C
Laxative
Laxative/Bowel Evacuant